leadf
logo-loader
ASX:CHM

Chimeric Therapeutics Ltd

Receive alerts
Market:
ASX
Market Cap:
$111.7 m
Price
0.34 AUD
Change
0.00%
52 weeks high
0.44
52 weeks low
0.24

In brief

Chimeric Therapeutics Ltd (ASX:CHM) is a clinical-stage company with a focus on research related to the usage of cell therapy for the treatment of cancer.

The company is developing CAR T cell therapies for solid tumours based on scientific research conducted by the US CAR T experts at the City of Hope Cancer Centre in Los Angeles.

Chimeric’s CLTX-CAR T technology incorporates chlorotoxin, a peptide derived from scorpion toxin, as a novel CAR tumour recognition domain.

Snapshot

  • Chimeric Therapeutics granted European patent for cancer-fighting asset CHM 1101
  • Chimeric Therapeutics licenses novel CAR T cell therapy with “transformative potential” from the University of Pennsylvania
  • Chimeric Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Chimeric Therapeutics licenses novel CAR T cell therapy with “transformative potential” from the University of Pennsylvania

Thanks to an exclusive licensing agreement with “a powerhouse in CAR T innovation”, Chimeric believes it is a step closer to bringing cell therapy to life for cancer patients.

on 28/7/21